Rectal Cancer
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)
- Details
ClinicalTrials.gov ID:
NCT03526835
Diagnosis Type:
NA
USOR Number:
- Address
,
P: